Biokin Pharmaceutical (688506.SH) subsidiary plans to invest USD 5 million in innovative drug company Connexus Therapeutics.

Zhito Finance APP News, Baili Tianheng (688506.SH) announced that, in order to broaden the company's layout in other cutting-edge technology tracks beyond its innovative ADC drug R&D platform (HIRE-ADC platform), innovative multi-specific antibody drug R&D platform (GNC platform), and specifically enhanced bispecific antibody platform (SEBA platform) and innovative ARC (radiopharmaceutical) R&D platform (HIRE-ARC platform), and to supplement the company's technology matrix. The company's wholly-owned subsidiary Pangu Capital intends to subscribe for 3.881 million Series A preferred shares of Connexus Therapeutics for US$5 million. After the completion of this capital increase, the company will hold a 7.91% equity interest in Connexus.